Trial Search Results

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Lung cancer is a common cause of morbidity and mortality, and even with modern imaging, lung cancer staging is inadequate. Involved regional lymph nodes often are not detectedand are subsequently ignored at the time of definitive surgery or radiation. This may lead to regional failures in otherwise curable patients. Our goal is to identify the primary lymph node drainage of lung cancer. With the results of this research, management could be more customized to individual patient circumstances, potentially improving outcomes.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Radiation: Computed Tomography (CT)
  • Device: Cyberknife
  • Device: Trilogy
  • Device: True Beam
  • Drug: Iohexol
  • Drug: Iodixanol





   - Either:

      - Established primary lung cancer/ cancer metastatic to lung, OR

      - Lesion suspicious for malignancy in lung, according to the following criteria:

         - Histopathologically confirmed lung cancer or cancer metastatic to lung, OR

         - Plan for biopsy of suspicious lung mass based on imaging (growth on serial
         CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR

         - Known metastatic cancer, with metastases to the lung based on imaging

   - Age > 18 years old

   - Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)

   - No prior surgery, chemotherapy, or radiation for the current lung tumor


   - Prior radiotherapy to thorax

   - Iodine allergy

   - Contraindication to receiving radiotherapy, unless undergoing surgery

   - Pregnant

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305